US health officials last week spoke about the need for more Pfizer vaccines. As a booster dose for all Americans over 65 or people as they can be at increased risk for the new coronavirus. In other words, in the coming weeks, the third dose will soon be offered in a broader vaccination program in the country. This will also include the immunization agents from Moderna and Janssen.
Now as per the reports this is also a fact that it will encourage the market. Since the booster dose could bring significant growth in sales and profits for manufacturers, in particular, Pfizer, which has already applied about 99 million vaccines…in the United States, followed by Moderna, with 68 million and Janssen with 14 million.
Wall Street is already aware of this movement. The average forecast among analysts for Moderna’s 2022 revenue, for example, has increased 35%. Since US President Joe Biden’s presentation of the reinforcement plan in August. “This opportunity will reflect billions of people around the world who need both the vaccine and a booster,” said Michael Yee, an analyst at Jefferies.Morningstar analyst Karen Andersen expects the extra doses to bring about $26 billion in global sales next year for Pfizer and BioN-Tech and about $14 billion for Moderna“if they are endorsed by a good part of the Americans”, he says.
The vaccine’s potential profits are harder to estimate for Pfizer, but company executives said they expect its profit margin to hover around $7 billion by 2022. Just with booster doses, based on Andersen’s sales forecast. Janssen and Britain’s AstraZeneca have stated that they do not intend to profit from their Covid-19 vaccines during the pandemic.
For Pfizer and Moderna, the boosts may be more profitable than the original doses. Because they won’t come with the research and development costs the companies had to get the vaccines to market. “The booster shots will represent almost pure profit compared to the initial ones,” said Steve Brozak, CEO of WBB Securities. Not counting the vaccines against variants of Sars-CoV-2 the drugmakers are already developing to serve as annual doses like the ones people get for the flu.